DOCSLIB.ORG

A 2020 Centenary Perspective on Neuromuscular Disorders Stephen a Goutman ‍ ‍ , Brian Christopher Callaghan ‍ ‍ , Eva Feldman ‍ ‍

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A 2020 Centenary Perspective on Neuromuscular Disorders Stephen a Goutman ‍ ‍ , Brian Christopher Callaghan ‍ ‍ , Eva Feldman ‍ ‍ 2020 Vision J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2020-324327 on 14 July 2020. Downloaded from A MODERN 2020 CENTENARY PERSPECTIVE ON TRAIL BLAZING PAPERS FROM THE JNNP ARCHIVE A 2020 centenary perspective on neuromuscular disorders Stephen A Goutman , Brian Christopher Callaghan , Eva Feldman last 100 years is remarkable. When JNNP able to create the groupings of patients first began publishing articles the struc- needed to begin deciphering the under- ture of DNA was unknown, and today we lying genetic causes of disease. These have effective gene-targeted therapies that groupings were in place as technology alter the course of multiple neuromuscular moved from linkage analysis to Sanger diseases. One year ago, we were chal- sequencing to next generation sequencing, lenged to consider the ‘most important or creating the clinical framework to detect transformative development in neurology’ the underlying defects in the genetic code. in the past 100 years and how JNNP contributed to this achievement given its GENE-BASED THERAPEUTIC TARGETS 3 broad scope. To our surprise, no nomi- At this writing, the GeneTable of nation for neuromuscular disorders made Neuromuscular Disorders (http://www. 4 the final list. Therefore, we wish to put musclegenetable.fr/ index. html) lists 587 forth a nomination for neuromuscular genes associated with 1042 disorders. disorders. All articles cited for this nomi- These include 97 entries for heredi- nation are published in JNNP. We contend Genetic diagnoses and gene-based tary motor sensory neuropathies, 50 for the subspeciality of neuromuscular disor- therapies have transformed our muscular dystrophies, 35 for congenital ders leads the neurologic community in muscular dystrophies, 44 for congenital approach to neuromuscular disorders the most important achievements in the myopathies, 30 for other myopathies, and created new therapies to treat last 100 years: discovering the genetic 19 for distal myopathies, 6 for myotonic previously incurable diseases aetiology of previously untreatable neuro- syndromes, 8 for ion channel muscle muscular disorders and turning these disorders, 29 for metabolic myopathies, copyright. discoveries into therapies. GENETIC DIagNOSES AND 71 for motor neuron disorders and 32 for congenital myasthenic syndromes. These GENE-BASED THERAPIES HavE DESCRIBE, DECIPHER, DETECT all represent potential targets for gene- TRANSFORMED OUR APPROACH TO So how did we get here? Quite literally by based treatments.8 NEUROMUSCULAR DISORDERS AND standing on the shoulders of giants. We Knowledge of these genes and func- CREATED NEW THERAPIES TO TREAT have relied on the dedication of pioneers tion enabled the development and recent PREVIOUSLY INCURABLE DISEASES that have come before us to describe and approval of drugs for SMA, specifically In August 1921, the Journal of Neurology, detail the diseases under this umbrella. the antisense oligonucleotide nusinersen9 Neurosurgery and Psychiatry (JNNP) Their detailed descriptions, such as those and the gene therapy onasemnogene,8 published a case of recurrent hypertro- by Anita Harding and Peter (PK) Thomas both of which led to not only the achieve- 1 http://jnnp.bmj.com/ phic neuritis, which detailed the clinical describing Kennedy’s disease and inher- ment of motor milestones in children with course of a patient with a likely inherited ited neuropathies,5 6 have helped shape SMA, but also a reduction in mortality neuropathy. Although unknown in 1921, our understanding of variability within the for this previously universally fatal condi- this article foreshadowed the critical role same diseases. It is only by understanding tion. These critical clinical achievements that genetics would play in altering the phenotypes, whether they be based on have led to mandatory SMA gene testing course of neuromuscular diseases in the history, examination or pathology, that in over half of the USA and has turned a next 100 years. In fact, 98 years later patients with the same disease can be lethal neuromuscular disorder in infants JNNP published a review on periph- grouped into common entities. These into a treatable possibly curable condi- on September 28, 2021 by guest. Protected eral neuropathy in complex inherited 2 broad groupings then become important tion. Similarly, transthyretin (TTR) diseases. As a group of disorders, neuro- as they provide clues to additional features amyloidosis began with identification of muscular diseases include entities that that alter disease. For example, consider the underlying genetic cause and patho- affect muscle, the neuromuscular junc- spinal muscular atrophy (SMA). Children physiology and evolved into a disease tion, peripheral nerves, nerve roots and with SMA type 1 have the same genetic with multiple gene- based therapies. We motor neurons. At each location, genetic mutation in survival motor neuron protein have antisense oligonucleotide (ASO) alterations can result in severe disease, (SMN) as children with SMA type 2, but and RNA interference medications that resulting in mild- to- severe disability for the expression of the SMN2 gene deter- can halt or even reverse the neuropathy those carrying mutations. The progress mines disease phenotype. The wide range experienced by these patients.10 SMA and made in our understanding of the genetic of phenotypes from early to later onset TTR amyloidosis are only two examples aetiology of neuromuscular diseases in the serve as the cornerstone for therapeutic of neuromuscular therapeutics. There development.7 These early pioneers that are currently a large number of gene Neurology, University of Michigan, Ann Arbor, Michigan, USA steadfastly catalogued the range of signs therapy studies listed on ClinicalT rials.gov and symptoms, and did so in a time prior ranging from those for X- Linked Myotu- Correspondence to Dr Eva Feldman, Ann Arbor, Michigan, USA; efeldman@ umich. edu to computerised disease registries, were bular Myopathy (NCT03199469), Limb Goutman SA, et al. J Neurol Neurosurg Psychiatry August 2020 Vol 91 No 8 791 2020 Vision J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2020-324327 on 14 July 2020. Downloaded from Girdle Muscular Dystrophy (LGMD) HavE YOUR SAY To cite Goutman SA, Callaghan BC, Feldman E. J Type 2C (NCT01344798), LGMD2D JNNP is asking readers to choose the Neurol Neurosurg Psychiatry 2020;91:791–792. (NCT01976091) and Becker Muscular most important or transformative devel- Received 19 June 2020 Dystrophy and Sporadic Inclusion Body opment in neurology, neurosurgery or Accepted 22 June 2020 Myositis (NCT01519349), to name a few. psychiatry in the past 100 years. To cast J Neurol Neurosurg Psychiatry 2020;91:791–792. These gene therapies are complimented your vote visit our website at https:// jnnp. doi:10.1136/jnnp-2020-324327 by ASO studies for Duchenne Muscular bmj. com/ pages/ jnnp- 100- a- centenary- of- ORCID iDs Dystrophy (NCT00159250), Myotonic publishing- neuroscience- achievement/. Stephen A Goutman http:// orcid. org/ 0000- 0001- 8780- Dystrophy Type 1 (NCT02312011), Voting closes on 15 August 2020. 6637 SOD1 Amyotrophic Lateral Sclerosis Brian Christopher Callaghan http:// orcid. org/ 0000- (NCT02623699) and C9ORF72 ALS 0002- 8885- 6748 Contributors SAG, BCC and EF were involved in all Eva Feldman http:// orcid. org/ 0000- 0002- 9162- 2694 (NCT04288856). Neuromuscular disor- aspects of the Editorial. ders leads the neurological community in Funding Support was provided by NIH NIEHS REFERENCES using our new understanding of genetic K23ES027221 (SAG) and the NeuroNetwork for 1 Nattrass FJ. Recurrent hypertrophic neuritis. J Neurol inheritance to develop and implement Emerging Therapies at University of Michigan (BCC Psychopathol 1921;2:159–65. effective therapies. and ELF). 2 Rossor AM, Carr AS, Devine H, et al. Peripheral Competing interests SAG consults with Biogen neuropathy in complex inherited diseases: an approach to diagnosis. J Neurol Neurosurg Psychiatry THE NEXT 100 YEARS and ITF Pharma. He also serves on an ALS DSMB via Watermark Research Partners. BCC consults for a 2017;88:846–63. What do the next 100 years hold? We PCORI grant, DynaMed, the Immune Tolerance Network 3 Kiernan MC. Milestones. J Neurol Neurosurg Psychiatry will leverage the knowledge gained by and performs medical legal consultations including 2019;90:1189. treating multiple patients with the same consultations for the Vaccine Injury Compensation 4 Kiernan MC. The Journal of Neurology, Neurosurgery mutation with the same drug to treat one Program. and Psychiatry centenary milestone award 2020. J Neurol Neurosurg Psychiatry 2020;91:677. patient with one genetic defect for a true Patient consent for publication Not required. 5 Harding AE, Thomas PK, Baraitser M, et al. X- Linked personalised approach to neuromuscular Provenance and peer review Commissioned; recessive bulbospinal neuronopathy: a report of ten diseases. Further, given the complexity internally peer reviewed. cases. J Neurol Neurosurg Psychiatry 1982;45:1012–9. of some neuromuscular diseases, we will 6 Harding AE, Thomas PK. Autosomal recessive forms harness the availability of new technology of hereditary motor and sensory neuropathy. J Neurol Neurosurg Psychiatry 1980;43:669–78. and large cohorts to find the polygenic 7 Wadman RI, Stam M, Gijzen M, et al. Association of causes of diseases where previously mono- motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0–4. J Neurol Neurosurg genetic causes were elusive. Next, we copyright.
Load more

Recommended publications
  • How a Silly Putty Ingredient Could Advance Stem Cell Therapies 13 April 2014
    How a Silly Putty ingredient could advance stem cell therapies 13 April 2014 carpet made of a key ingredient in Silly Putty. Their study is published online at Nature Materials on April 13. This research is the first to directly link physical, as opposed to chemical, signals to human embryonic stem cell differentiation. Differentiation is the process of the source cells morphing into the body's more than 200 cell types that become muscle, bone, nerves and organs, for example. Jianping Fu, U-M assistant professor of mechanical engineering, says the findings raise the possibility of a more efficient way to guide stem cells to differentiate and potentially provide therapies for diseases such as amyotrophic lateral sclerosis (Lou Gehrig's disease), Huntington's or Alzheimer's. In the specially engineered growth system—the 'carpets' Fu and his colleagues designed—microscopic posts of the Silly Putty component polydimethylsiloxane serve as the threads. By varying the post height, the researchers can adjust the stiffness of the surface they grow cells on. Shorter posts are more rigid—like an industrial carpet. Taller ones are softer—more plush. University of Michigan researchers have found that mechanical forces in the environment of human embryonic stem cells influences how they differentiate, The team found that stem cells they grew on the or morph into the body's different cell types. To arrive at tall, softer micropost carpets turned into nerve cells the findings, they cultured the stem cells on ultrafine much faster and more often than those they grew carpets made of microscopic posts of a key ingredient in on the stiffer surfaces.
    [Show full text]
  • Practiceupdateadc2018
    ‘There Is More to Neuropathy Than Hyperglycemia Alone in T2D’ BY THE PRACTICEUPDATE EDITORIAL TEAM ne of America’s top neurologists says that the “This told us that we have to move away from the underlying pathogenesis of neuropathy in glucose-centric idea that neuropathy in type 2 dia- type 2 diabetes (T2D) is likely the metabolic betes is just caused by hyperglycemia,” Professor Osyndrome, rather than solely hyperglycemia. Feldman said. As such, consuming healthy foods and increasing In Australia, approximately half of all patients with T2D exercise may be the answer to preventing neuropa- are thought to have diabetic neuropathy. thy brought on by the metabolically induced changes “We know that neuropathy is the leading predictor of in peripheral nerves of patients with type 2 diabetes, mortality in a patient with diabetes, and that it leads said Eva Feldman, MD, PhD, Professor of Neurology to poor quality of life, pain, depression, and ulcers at the University of Michigan in Ann Arbor, Michigan. and amputation. “We know that in type 1 diabetes, there is a clear “In the US alone, diabetic neuropathy costs the US decrease in the incidence and prevalence of diabetic government about $60 billion annually in healthcare neuropathy with good glucose control. But in patients costs,” Professor Feldman said. with type 2 diabetes, controlling glucose has very little efect on neuropathy. Metabolic reprogramming of nerve bioenergetics “And what we saw is that the more components of the In a simple clinical trial conducted at the University of metabolic syndrome a patient has, the more likely Michigan, Professor Feldman and her team recruited they are to have neuropathy.
    [Show full text]
  • Smart Ways to Manage Neuropathy Neuropathy, a Common Complication of Diabetes, Was Once Thought to Be Untreatable
    PAIN APRIL/MAY 2018 BY GINA SHAW Smart Ways to Manage Neuropathy Neuropathy, a common complication of diabetes, was once thought to be untreatable. Today, a variety of treatments and strategies are available to ease the discomfort. By the time she was in her early fifties, Kathy Zimmerman knew she had to make a change. The computer software engineer in Springfield, VA, had steadily gained weight over the years until she was morbidly obese and had developed type 2 diabetes. "I had a number of other health problems, too, including arthritis and high blood pressure," says Zimmerman, now 67. Then she started noticing numbness, tingling, and burning in her feet and was told she had diabetic peripheral neuropathy—nerve damage caused by exposure to high blood sugar and the other metabolic consequences of diabetes. Although researchers are still investigating exactly how diabetes damages nerve cells, many believe it may be a result of metabolic changes that increase inflammation—changes that are also exacerbated by high cholesterol, high blood pressure, obesity, and smoking. Illustration by Jun Cen All Too Common Nearly 60 percent of all people with diabetes have some form of neuropathy, most often in their feet. It affects people with both type 1 and type 2 diabetes: About 20 percent of type 1 patients develop it after 20 years, and about 50 percent of type 2 patients develop it after just 10 years. (In type 1 diabetes, the body's immune system destroys the cells needed to produce insulin, which means the pancreas cannot process the sugar, known as glucose, it needs to produce energy.
    [Show full text]
  • DOWNLOAD Emerging Scholars Brochure
    EMERGING SCHOLARS PROGRAM The Emerging Scholars Program The NeuroNetwork for Emerging Therapies at Michigan Medicine Emerging Scholars Program intends to assure that there is a solid future for our next generation of medical science leaders and the many cures and treatments that will be their legacy. The NeuroNet has talented young scientists who require funding to pursue innovative approaches to the treatment of disease and build the credentials they need to secure long-term financial support for their research from private foundations and the National Institutes of Health. Emerging Scholars funding typically involves a $150,000 commitment, which is spread equally over three years. During that time, donors receive biannual reports from their Emerging Scholar about the research they are supporting, as well as an opportunity to meet with their Emerging Scholar to learn first-hand the impact their gift has made in the battle against disease. Support for the Emerging Scholars Program also may be made through the University of Michigan’s endowment. A gift of $500,000 allows for the establishment of a permanent Emerging Scholar Fund, which can support young scientists working in a designated field of medicine. This allows a donor’s commitment to medical research to live on in perpetuity. emerging scholar candidates Dr. Claudia Dr. Brian Callaghan Dr. Kevin Chen Dr. Sarah Elzinga Dr. Stephen Goutman Dr. Osama Kashlan Figueroa-Romero Dr. Bhumsoo Kim Dr. Benjamin Murdock Dr. Phillipe O’Brien Dr. Evan Reynolds Dr. Amy Rumora NeuroNetwork for Emerging Therapies Lisa McGinley, PhD Handleman Emerging Scholar • Alzheimer’s Disease Research Assistant Professor, Department of Neurology Translating stem cell therapy to treat Alzheimer’s disease Dr.
    [Show full text]
  • Eva L. Feldman, M.D., Ph.D
    Eva L. Feldman, M.D., Ph.D., Throughout her career, Dr. Eva Feldman, the Russell N. DeJong Professor of Neurology at the University of Michigan, has made it her mission to use scientific discoveries to understand and cure human diseases. In January 2008, Dr. Feldman was named the first Director of the A. Alfred Taubman Medical Research Institute, which was created to support the translational research of physicians-scientists at the University of Michigan on a variety of diseases, particularly neurodegenerative diseases, diabetes and other metabolic disorders, cardiovascular disease and adult and childhood cancer (www.taubmaninstitute.org). Under her leadership, the A. Alfred Taubman Medical Research Institute has garnered national recognition by being one of the few facilities in the United States to produce disease specific embryonic stem cell lines. In addition, Dr. Feldman directs a laboratory of 35 scientists who collaborate on the discovery of new treatments for a wide range of neurological diseases, with an emphasis on regenerative medicine and the use of stem cells as a novel therapy in neurological disorders. She is the Principle Investigator on the first FDA approved trial of intraspinal stem cell transplantation in amyotrophic lateral sclerosis, and currently serves this same role in the Phase 2 trial. She is the author of more than 300 articles, 61 book chapters and three books. She is the Principal Investigator of five major National Institutes of Health research grants, two private foundation grants and five clinical trials focused on understanding and treating neurological disorders, with an emphasis on diabetic neuropathy. She is the immediate President of the American Neurological Association and a Past President of the Peripheral Nerve Society.
    [Show full text]
  • LETTER from the CHAIR Academic Rigor, Mentorship, & Compassion Pave the Way to Clinical Excellence
    ISSUE 13 2015 - 2016 LETTER FROM THE CHAIR Academic Rigor, Mentorship, & Compassion Pave the Way to Clinical Excellence Within the Department of Neurosurgery, we have always had as our Mentorship has played an important role in our growth; its importance motto that we focus on, “Our patients…past, present, and future.” has been demonstrated not only by our faculty and residents, but in all With this patient-centered approach, we have been fortunate to see areas of the Department. Professional growth and development have been excellence in many areas. key elements to success at all levels within the Department. I personally was fortunate enough to have a delightful session with Dr. Sanjay Gupta, Under the leadership of Dr. Greg Thompson, Program Director, in which he spoke to the importance of mentorship for himself and for our residents have continued to demonstrate the true meaning of others and particularly how his time here at the University of Michigan accomplishment. They have been chosen for outstanding fellowships helped shape his own practice. and positions in academic neurosurgery and practices throughout the country. Publications from both our residents and faculty have grown Within our Department, individual leadership has led to team efforts to consistently in recent years. Our alumni have gone on to become provide food, clothing, and school supplies for a variety of organizations esteemed members at a variety of institutions with now six sitting that provide for those in need. These efforts have all been organized by Chairs of neurosurgical departments counted among the graduates of our administrative staff. Additionally, Project Shunt, our outreach program our neurosurgical residency.
    [Show full text]
  • Message from the Chair
    2015 Message from the Chair I am very pleased to be able to bring you up to date on funding ($10 million NIH)—a figure that doesn’t include the Michigan Neurology. Since the last edition of this newsletter recently awarded Udall (Parkinson’s) Center grant and the that was published in winter 2012, our department has Sudden Unexpected Death in Epilepsy (SUDEP) Center continued to grow. We now have 61 physician faculty, Without Walls grant highlighted in this issue. 18 residents and more than 20 post-residency trainees Having completed 10 years as chair, I am more aware than in subspecialties ranging from stroke and sleep to sports ever that a department is not a static entity, but a continuously neurology. evolving functional unit. With the formal installation of The growth in faculty is reflected in clinical activity. Last Hiroko Dodge, Ph.D. as the first Kevreson Research Professor year our faculty saw nearly 40,000 outpatient visits—almost this spring, we will have 14 endowed professorships that twice the number of patient visits recorded in 2007—and recognize the accomplishments of our more senior faculty, activity in all of the related laboratories including EMG, and 10 assistant professors with NIH-funded K (mentored EEG and the 28-bed sleep lab increased commensurately. career development) awards that recognize promise for the In the research arena, our faculty has continued to be future leaders of the field. These 24 faculty are only part of very successful, even in the face of a challenging funding our group of clinicians, educators and researchers.
    [Show full text]
  • STEM CELL THERAPY Eva Feldman Russell N. Dejong Professor of Neurology, University of Michigan, USA
    BEST FUTURE STRATEGIES FOR NEUROREHABILITATION - STEM CELL THERAPY Eva Feldman Russell N. DeJong Professor of Neurology, University of Michigan, USA Neurodegenerative diseases are increasing at an alarming rate as the worldwide population ages. There are few effective treatments for these disorders that include Alzheimer’s disease (AD), Parkinson’s and Huntington’s disease, and amyotrophic lateral sclerosis (ALS). Cellular therapies offer a unique opportunity to delay or even improve the clinical course of these disorders. Treatment objectives typically center on cellular replacement or providing environmental enrichment. The two most common approaches involve the transplantation of fetal tissue grafts or of stem cells, the focus of today’s debate. Stem cells have the capacity to proliferate and differentiate into multiple cellular lineages. There are different classifications of stem cells that reflect the range of possible cell types they can produce, and include embryonic stem (ES) cells, progenitor cells, mesenchymal stem cells (MSCs), and induced pluripotent stem (iPS) cells. Stem cells may provide cellular replacement, or more commonly provide environmental enrichment to support host neurons by producing neurotrophic factors, scavenging toxic factors or creating auxiliary neural networks around affected areas and improving neural circuitry. Many strategies for environmental enrichment utilize stem cells to provide de novo synthesis and delivery of neuroprotective growth factors at the site of disease. Neural progenitor stem cells are currently being transplanted into the spinal cords of patients with ALS and multiple transplants alter the normal relentless progression of the disease. While more research is required, including highly controlled clinical trials, recent success with cellular therapy in ALS provides the beginning of a new therapeutic era in neurodegenerative disorders.
    [Show full text]
  • Informed Consent Form
    Study ID: HUM00039723 IRB: IRBMED Date Approved: 11/8/2018 Expiration Date: 11/7/2019 UNIVERSITY OF MICHIGAN CONSENT TO BE PART OF A RESEARCH STUDY INFORMATION ABOUT THIS FORM You may be eligible to take part in a research study. This form gives you important information about the study. It describes the purpose of the study, and the risks and possible benefits of participating in the study. Please take time to review this information carefully. After you have finished, you should talk to the researchers about the study and ask them any questions you have. You may also wish to talk to others (for example, your friends, family, or other doctors) about your participation in this study. If you decide to take part in the study, you will be asked to sign this form. Before you sign this form, be sure you understand what the study is about, including the risks and possible benefits to you. 1. GENERAL INFORMATION ABOUT THIS STUDY AND THE RESEARCHERS 1.1 Study title: The impact of metabolic syndrome on the incidence of neuropathy in obese subjects. 1.2 Company or agency sponsoring the study: A. Alfred Taubman CA&UP Administration American Diabetes Association Impeto Medical Neurology Department Department of Health and Human Services, National Institutes of Health 1.3 Names, degrees, and affiliations of the researchers conducting the study: Dr. Brian Callaghan, M.D. Principal Investigator Dr. Charles Burant, M.D., Ph.D. Co- Investigator Dr. Eva Feldman, M.D, Ph.D. Co- Investigator Dr. Rodica Pop-Busui, M.D. Co- Investigator Dr.
    [Show full text]
  • Feldman, Eva (2009)
    Animal Models of Diabetic Complications Consortium (U01 DK076160) Annual Report (2009) “Mitochondrial SOD as a Target for Diabetic Neuropathy” University of Michigan Principal Investigator Eva L. Feldman, M.D., Ph.D. Address: University of Michigan Department of Neurology 109 Zina Pitcher Road 5017 BSRB Ann Arbor MI 48109-2200 Phone: (734) 763-7274 E-mail: [email protected] 1 Table of Contents Page Part A: Principal Investigator’s Summary 3-21 1. Project Accomplishments (2009) 4-13 2. Collaboration 13-15 3. Address previous EAC comments 15-19 4. Publications 19-20 Part B: Individual Project Reports by Responsible Investigator (if applicable) NA 2 Animal Models of Diabetic Complications Consortium (U01 DK076160) Part A: Principal Investigator’s Summary 3 1. Program Accomplishments: Hypothesis: We continue to investigate the damaging effects of diabetes-induced oxidative stress on the nervous system. Our primary goal is examining the onset and progression of diabetic polyneuropathy (DPN). Recent data collected from our archived human samples indicates that elevated triglycerides predict the progression of DPN in human patients (1). We have confirmed the damaging effects of oxidized lipids on neuronal oxidative stress and DPN progression in an animal model of type 2 diabetes, high fat fed C57Bl/6J mice (2). We are also investigating the role of diabetes induced oxidative stress, dyslipidemia and insulin resistance on neurons of the central nervous system with regard to the pathology of Alzheimer’s disease. The results of these two studies are detailed below. Progress Towards Stated Milestones: Dyslipidemia-Induced Neuropathy in Mice We investigated the impact of a high fat diet on the induction of insulin resistance, dyslipidemia and neuropathy in C57Bl/6J mice.
    [Show full text]
  • Spring2005.Pdf
    Dear Alumni and Friends: It is sometimes easy to forget, as we no access to quality health care or advanced procedures (page make our way in haste through the 30). Dozens of surgeries performed within a week are not bustling halls, clinics, labs and lecture uncommon for short-term missions, but that impact is com- rooms of the Medical School, that med- pounded many times over by giving medical personnel in icine at Michigan reaches far beyond the these countries the opportunity to observe improved tech- Ann Arbor campus and satellite clinics niques and updated methods of care. Helping to establish eye of the U-M Health System. This issue of banks in Mongolia, providing doctors with the latest tech- Medicine at Michigan highlights two of niques for helping children with disabilities in Malawi, work- the extraordinary ways in which the ing to secure needed equipment and supplies for communities brilliance and commitment that charac- in Guatemala — in ways such as these, U-M health care pro- terize our school and health system are fessionals are sharing their knowledge and skills. taken to some of the farthest reaches of In an age when disease can travel as fast and as far as jet air- our planet, often to those who need it most desperately. planes, and cultures merge in the conduct of global business, It is at once remarkable and to be expected, given the caliber it is the obligation of any great academic institution to bring of students who study medicine and biomedical research at its resources to bear on problems and issues outside the strict the U-M, that many of the international initiatives which bear confines and limits of its campus, city or state.
    [Show full text]
  • Diabetes Care and Reearch at UM
    Photo: Paul Thacker Photo: Paul by Whitley Hill 36 Spring/Summer 2004 Photo: Paul Thacker Photo: Paul he invisible epidemic: that’s “I was 29, working Jackson was admitted to what the American Diabetes at the U-M Office Michigan’s comprehen- T Association calls the disease of Administrative sive, six-day inpatient that last year took the lives of 170,000 Systems as a techni- program where her blood Americans, a number that continues to cal writer. I was liv- glucose levels were stabi- rise. Each year, 25,000 new cases of ing alone and had a lized. She consulted with blindness are caused by diabetes. It is the boyfriend; I was dietitians, attended group most common cause of renal failure in playing a lot of fid- sessions with other newly the country. Today, diabetes is the fourth dle music. I can say diagnosed people, and leading cause of death by disease in the that I never even began to learn to accept U.S. Nearly 20 million Americans have mentioned the word the reality of life with a this disease. A third of them don’t even ‘diabetes’ in my life. Martha Funnell chronic, potentially seri- know. Then suddenly I ous disease. started to lose weight and was walking But it doesn’t have to be this way. Every “I felt overwhelmed,” she recalls. “I around with a water bottle, chips, candy day at the University of Michigan, some took every instruction very seriously. bars. I was always hungry but I kept los- of the world’s best and brightest scien- Eat at the same time every day.
    [Show full text]